Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer

Endocrinology

Volumn 144, Issue 5, 2003, Pages 1656-1663

  Liao, Xinbo ^a   Thrasher, J Brantley ^a   Pelling, Jill ^b   Holzbeierlein, Jeffery ^a   Sang, Qing Xiang Amy ^c   Li, Benyi ^a,b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c FLORIDA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANDROGEN RECEPTOR; BICALUTAMIDE; CYCLOHEXIMIDE; DACTINOMYCIN; GELATINASE A; LUCIFERASE; METRIBOLONE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RNA; WORTMANNIN; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; ENZYME INHIBITOR; HYDROXAMIC ACID; MORPHOLINE DERIVATIVE; N HYDROXY 9 OCTADECENAMIDE; N-HYDROXY-9-OCTADECENAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PRODRUG; TESTOSTERONE DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; HORMONE ACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RNA TRANSCRIPTION; WESTERN BLOTTING; ZYMOGRAPHY; CELL CULTURE; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TRANSACTIVATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL MOVEMENT; CHROMONES; ENZYME INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; MATRIX METALLOPROTEINASE 2; METRIBOLONE; MORPHOLINES; PRODRUGS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TESTOSTERONE CONGENERS; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED;

EID: 0038561224     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2002-0157     Document Type: Article

References (54)

1. Jemal A, Thomas A, Murray T 2002 Cancer statistics. CA Cancer J Clin 52:23-47
2. Huggins C, Hodges CV 1941 Studies on prostatic cancer: the effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297
3. Denmeade SR, Lin XS, Isaacs JT 1996 Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28:251-265
4. Coussens LM, Fingleton B, Matrisian LM 2002 Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387-2392
5. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M 1994 A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370:61-65
6. Upadhyay J, Shekarriz B, Nemeth JA, Dong Z, Cummings GD, Fridman R, Sakr W, Grignon DJ, Cher ML 1999 Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res 5:4105-4110
7. Wilson MJ, Sellers RG, Wiehr C, Melamud O, Pei D, Peehl DM 2002 Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. J Cell Physiol 191:208-216
8. Lokeshwar BL 1999 MMP inhibition in prostate cancer. Ann NY Acad Sci 878:271-289
9. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL 1997 Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 3:402-408
10. Li H, Bauzon DE, Xu X, Tschesche H, Cao J, Sang QA 1998 Immunological characterization of cell-surface and soluble forms of membrane type 1 matrix metalloproteinase in human breast cancer cells and in fibroblasts. Mol Carcinog 22:84-94
11. Heussen C, Dowdle EB 1980 Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 102:196-202
12. Nagakawa O, Ogasawara M, Murata J, Fuse H, Saiki 12001 Effect of prostatic neuropeptides on migration of prostate cancer cell lines. Int J Urol 8:65-70
13. Bian J, Sun Y 1997 Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 17:6330-6338
14. Qin H, Sun Y, Benveniste EN 1999 The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 1999 274:29130-29137
15. Shimajiri S, Arima N, Tanimoto A, Murata Y, Hamada T, Wang KY, Sasaguri Y 1999 Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett 455:70-74
16. Xie X, Zhao X, Liu Y, Young CYF, Tindall DJ, Slawin KM, Spencer DM 2001 Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 (hK2) promoter. Hum Gene Ther 12:549-561
17. Spencer DM, Wandless TJ, Schreiber SL, Crabtree GR 1993 Controlling signal transduction with synthetic ligands. Science 262:1019-1024
18. Van Steenbrugge GJ, van Uffelen CJ, Bolt J, Schroder FH 1991 The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. J Steroid Biochem Moi Biol 40:207-214
19. Zucker S, Mancuso P, DiMassimo B, Lysik RM, Conner C, Wu CL 1994 Comparison of techniques for measurement of gelatinases/type IV collagenases: enzyme-linked immunoassays versus substrate degradation assays. Clin Exp Metastasis 12:13-23
20. Patterson BC, Sang QA 1997 Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatmase B/type IV collagenase (MMP-9). J Biol Chem 222:28823-28825
21. Shakil T, Hoque AN, Husain M, Belsham DD 2002 Differential regulation of gonadotropin-releasing hormone secretion and gene expression by androgen: membrane versus nuclear receptor activation. Mol Endocrinol 16:2592-2602
22. Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M 2000 Multiple actions of steroid hormones - a focus on rapid, nongenomic effects. Pharmacol Rev 52:513-556
23. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP 2002 Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 277:26321-26326
24. Waller AS, Sharrard RM, Berthon P, Maitland NJ 2000 Androgen receptor localization and turnover in human prostate epithelium treated with the antiandrogen, bicalutamide. J Mol Endocrinol 24:339-351
25. Hanemaaijer R, Koolwijk P, le Clercq L, de Vree WJ, van Hinsbergh VW 1993 Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor α, interleukin 1 and phorbol ester. Biochem J 296:803-809
26. Brown PD, Levy AT, Margulies IM, Liotta LA, Stetler-Stevenson WG 1990 Independent expression and cellular processing of Mr 72, 000 type W collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res 50:6184-6191
27. Nagakawa O, Murakami K, Yamaura T, Fujiuchi Y, Murata J, Fuse H, Saiki I 2000 Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett 155:173-179
28. Han YP, Tuan TL, Wu H, Hughes M, Garner WL 2001 TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-κB mediated induction of MT1-MMP. J Cell Sci 114:131-139
29. Li P, Nicosia SV, Bai W 2001 Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. J Biol Chem 276:20444-20050
30. Sharma M, Chuang WW, Sun Z 2002 Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3β inhibition and nuclear β-catenin accumulation. J Biol Chem 277:30935-30941
31. Manin M, Baron S, Goossens K, Beaudoin C, Jean C, Veyssiere G, Verhoeven G, Morel L 2002 Androgen receptor expression is regulated by PI3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem J 366:729-736
32. Raffioni S, Bradshaw RA 1992 Activation of phosphatidylinositol 3-kinase by epidermal growth factor, basic fibroblast growth factor, and nerve growth factor in PC12 pheochromocytoma cells. Proc Natl Acad Sci USA 89:9121-9125
33. Graves LM, Northrop JL, Ports BC, Krebs EG, Kimelman D 1994 Fibroblast growth factor, but not activin, is a potent activator of mitogen-activated protein kinase in Xenopus explants. Proc Natl Acad Sci USA 91:1662-1666
34. Miyake H, Yoshimura K, Hara I, Eto H, Arakawa S, Kamidono S 1997 Basic fibroblast growth factor regulates matrix metalloproteinases expression and in vitro invasiveness in human bladder cancer cell lines. J Urol 157:2351-2355
35. Stamenkovic I 2000 Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10:415-433
36. Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE, Parsons JT 2001 Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene 20:1152-1163
37. Emonard H, Marcq V, Mirand C, Hornebeck W 1999 Inhibition of gelatinase A by oleic acid. Ann N Y Acad Sci 878:647-649
38. Jimenez C, Portela RA, Mellado M, Rodriguez-Frade JM, Collard J, Serrano A, Martinez-A C, Avila J, Carrera AC 2000 Role of the P13K regulatory subunit in the control of actin organization and cell migration. J Cell Biol 151:249-262
39. Mauviel A 1993 Cytokine regulation of metalloproteinase gene expression. J Cell Biochem 53:288-295
40. Hasan S, Nakajima M 1999 Retinoic acid synergizes with cyclic AMP to enhance MMP-2 basal promoter activity. Biochem Biophys Res Commun 258:663-667
41. Singh RK, Gutman M, Reich R, Bar-Eli M 1995 Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin 8. Cancer Res 55:3669-3674
42. Yu M, Sato H, Seiki M, Thompson EW 1995 Complex regulation of membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation by concanavalin A in MDA-MB-231 human breast cancer cells. Cancer Res 55:3272-3277
43. Hujanen ES, Vaisanen A, Zheng A, Tryggvason K, Turpeenniemi-Hujanen T 1994 Modulation of M(r) 72, 000 and M(r) 92, 000 type-IV collagenase (gelatinase A and B) gene expression by interferons α and γin human elanoma. Int J Cancer 58:582-586
44. Garbisa S, Pozzatti R, Muschel RJ, Saffiotti U, Ballin M, Goldfarb RH, Khoury G, Liotta LA 1987 Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-E1a. Cancer Res 47:1523-1528
45. Park BK, Zeng X, Glazer RI 2001 Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res 61:7647-7653
46. Nakajima M, Lotan D, Baig MM, Carralero RM, Wood WR, Hendrix MJ, Lotan R 1989 Inhibition by retinoic acid of type IV collagenolysis and invasion through reconstituted basement membrane by metastatic rat mammary adenocarcinoma cells. Cancer Res 49:1698-1706
47. Kohn EC, Jacobs W, Kim YS, Alessandro R, Stetler-Stevenson WG, Liotta LA 1994 Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A). J Biol Chem 269:21505-21511
48. Li SC, Chen GF, Chan PS, Choi HL, Ho SM, Chan FL 2001 Altered expression of extracellular matrix and proteinases in Noble rat prostate gland after long-term treatment with sex steroids. Prostate 49:58-71
49. Moalli PA, Klingensmith WL, Meyn LA, Zyczynski HM 2002 Regulation of matrix metalloproteinase expression by estrogen in fibroblasts that are derived from the pelvic floor. Am J Obstet Gynecol 187:72-79
50. Gelmann EP 2002 Molecular biology of the androgen receptor. J Clin Oncol 20:3001-3015
51. Schneikert J, Peterziel H, Defossez PA, Klocker H, Launoit Y, Cato AC 1996 Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. J Biol Chem 271:23907-23913
52. Claessens F, Verrijdt G, Schoenmakers E, Haelens A, Peeters B, Verhoeven G, Rombauts W 2001 Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation. J Steroid Biochem Moi Biol 76:23-30
53. Koul D, Parthasarathy R, Shen R, Davies MA, Jasser SA, Chintala SK, Rao JS, Sun Y, Benvenisite EN, Liu TJ, Yung WK 2001 Suppression of matrix metalioproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 20:6669-6678
54. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J 1998 Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58:2720-2723